{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T21:33:19Z","timestamp":1792359199649,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["ME 1303 5785"],"award-info":[{"award-number":["ME 1303 5785"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-019-3581-3","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T09:15:03Z","timestamp":1567761303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6126-2459","authenticated-orcid":false,"given":"Evan","family":"Mayo-Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwanhee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Canner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Dickersin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"3581_CR1","volume-title":"42 CFR Part 11. Clinical trials registration and results information submission: Final rule","author":"Department of Health and Human Services","year":"2016","unstructured":"Department of Health and Human Services. 42 CFR Part 11. Clinical trials registration and results information submission: Final rule. 2016. \n                    https:\/\/www.federalregister.gov\/documents\/2016\/09\/21\/2016-22129\/clinical-trials-registration-and-results-information-submission\n                    \n                  . Accessed 12 May 2018."},{"issue":"20","key":"3581_CR2","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMsr1611785","volume":"375","author":"DA Zarin","year":"2016","unstructured":"Zarin DA, Tse T, Williams RJ, et al. Trial reporting in ClinicalTrials. gov\u2014the final rule. N Engl J Med. 2016;375(20):1998\u20132004. \n                    https:\/\/doi.org\/10.1056\/NEJMsr1611785\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"3581_CR3","volume-title":"CFR Title 21, Section 312. Investigational new drug application","author":"Department of Health and Human Services","year":"2010","unstructured":"Department of Health and Human Services. CFR Title 21, Section 312. Investigational new drug application, 2010."},{"key":"3581_CR4","volume-title":"Guideline on good pharmacovigilance practices (GVP): Annex I - Definitions (Rev 4)","author":"European Medicines Agency","year":"2017","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Annex I - Definitions (Rev 4), 2017. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/05\/WC500143294.pdf\n                    \n                  . Accessed 12 May 2018."},{"key":"3581_CR5","volume-title":"CFR Title 21, Section 312.32. IND safety reporting","author":"Department of Health and Human Services","year":"2010","unstructured":"Department of Health and Human Services. CFR Title 21, Section 312.32. IND safety reporting. 2010. \n                    https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRsearch.cfm?CFRPart=312\n                    \n                  . Accessed 12 May 2018."},{"key":"3581_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0889-8588(05)70309-9","volume":"77","author":"S Golder","year":"2016","unstructured":"Golder S, Loke YK, Wright K, et al. Most systematic reviews of adverse effects did not include unpublished data. J Clin Epidemiol. 2016;77:125\u201333. \n                    https:\/\/doi.org\/10.1016\/S0889-8588(05)70309-9\n                    \n                  .","journal-title":"J Clin Epidemiol"},{"key":"3581_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jclinepi.2018.12.007","volume":"108","author":"R Parsons","year":"2019","unstructured":"Parsons R, Golder S, Watt I. More than one-third of systematic reviews did not fully report the adverse events outcome. J Clin Epidemiol. 2019;108:95\u2013101. \n                    https:\/\/doi.org\/10.1016\/j.jclinepi.2018.12.007\n                    \n                  .","journal-title":"J Clin Epidemiol"},{"issue":"26","key":"3581_CR8","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1056\/NEJMp1409464","volume":"371","author":"S Bonini","year":"2014","unstructured":"Bonini S, Eichler H-G, Wathion N, et al. Transparency and the European Medicines Agency\u2014sharing of clinical trial data. N Engl J Med. 2014;371(26):2452\u20135.","journal-title":"N Engl J Med"},{"issue":"5","key":"3581_CR9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jamainternmed.2013.3838","volume":"173","author":"P Doshi","year":"2013","unstructured":"Doshi P, Jefferson T. The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer. JAMA Intern Med. 2013;173(5):380\u20132.","journal-title":"JAMA Intern Med"},{"key":"3581_CR10","volume-title":"FDA Commissioner Scott Gottlieb, M.D., on new steps FDA is taking to enhance transparency of clinical trial information to support innovation and scientific inquiry related to new drugs [press release]","author":"U.S. Food and Drug Administration","year":"2018","unstructured":"U.S. Food and Drug Administration. FDA Commissioner Scott Gottlieb, M.D., on new steps FDA is taking to enhance transparency of clinical trial information to support innovation and scientific inquiry related to new drugs [press release]. 2018."},{"issue":"25","key":"3581_CR11","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1056\/NEJMp1605348","volume":"374","author":"BE Bierer","year":"2016","unstructured":"Bierer BE, Li R, Barnes M, et al. A global, neutral platform for sharing trial data. N Engl J Med. 2016;374(25):2411\u20133.","journal-title":"N Engl J Med"},{"issue":"5","key":"3581_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMp1607342","volume":"375","author":"HM Krumholz","year":"2016","unstructured":"Krumholz HM, Waldstreicher J. The Yale Open Data Access (YODA) project\u2014a mechanism for data sharing. N Engl J Med. 2016;375(5):403\u20135.","journal-title":"N Engl J Med"},{"key":"3581_CR13","doi-asserted-by":"publisher","first-page":"180268","DOI":"10.1038\/sdata.2018.268","volume":"5","author":"JS Ross","year":"2018","unstructured":"Ross JS, Waldstreicher J, Bamford S, et al. Overview and experience of the YODA project with clinical trial data sharing after 5 years. Sci Data. 2018;5:180268.","journal-title":"Sci Data"},{"issue":"3","key":"3581_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jama.1992.03480030052036","volume":"267","author":"K Dickersin","year":"1992","unstructured":"Dickersin K, Min Y-I, Meinert CL. Factors influencing publication of research results: follow-up of applications submitted to two institutional review boards. JAMA. 1992;267(3):374\u20138. \n                    https:\/\/doi.org\/10.1001\/jama.1992.03480030052036\n                    \n                  .","journal-title":"JAMA"},{"issue":"7","key":"3581_CR15","doi-asserted-by":"publisher","first-page":"e66844","DOI":"10.1371\/journal.pone.0066844","volume":"8","author":"K Dwan","year":"2013","unstructured":"Dwan K, Gamble C, Williamson PR, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review. PLoS One. 2013;8(7):e66844. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0066844\n                    \n                  .","journal-title":"PLoS One"},{"issue":"7494","key":"3581_CR16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1136\/bmj.38356.424606.8F","volume":"330","author":"AW Chan","year":"2005","unstructured":"Chan AW, Altman DG. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ. 2005;330(7494):753\u20136. \n                    https:\/\/doi.org\/10.1136\/bmj.38356.424606.8F\n                    \n                  .","journal-title":"BMJ"},{"issue":"20","key":"3581_CR17","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1001\/jama.291.20.2457","volume":"291","author":"AW Chan","year":"2004","unstructured":"Chan AW, Hrobjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials - comparison of protocols to published articles. JAMA. 2004;291(20):2457\u201365. \n                    https:\/\/doi.org\/10.1001\/jama.291.20.2457\n                    \n                  .","journal-title":"JAMA"},{"issue":"7","key":"3581_CR18","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1503\/cmaj.1041086","volume":"171","author":"AW Chan","year":"2004","unstructured":"Chan AW, Krieza-Jeric K, Schmid I, et al. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. Can Med Assoc J. 2004;171(7):735\u201340. \n                    https:\/\/doi.org\/10.1503\/cmaj.1041086\n                    \n                  .","journal-title":"Can Med Assoc J"},{"issue":"6","key":"3581_CR19","doi-asserted-by":"publisher","first-page":"e1001666","DOI":"10.1371\/journal.pmed.1001666","volume":"11","author":"K Dwan","year":"2014","unstructured":"Dwan K, Altman DG, Clarke M, et al. Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials. PLoS Med. 2014;11(6):e1001666. \n                    https:\/\/doi.org\/10.1371\/journal.pmed.1001666\n                    \n                  .","journal-title":"PLoS Med"},{"key":"3581_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jclinepi.2017.05.007","volume":"86","author":"E Mayo-Wilson","year":"2017","unstructured":"Mayo-Wilson E, Fusco N, Li T, et al. Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis. J Clin Epidemiol. 2017;86:39\u201350. \n                    https:\/\/doi.org\/10.1016\/j.jclinepi.2017.05.007\n                    \n                  .","journal-title":"J Clin Epidemiol"},{"issue":"20","key":"3581_CR21","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMsa0906126","volume":"361","author":"SS Vedula","year":"2009","unstructured":"Vedula SS, Bero L, Scherer RW, et al. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009;361(20):1963\u201371. \n                    https:\/\/doi.org\/10.1056\/NEJMsa0906126\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"3581_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jclinepi.2019.04.020","volume":"113","author":"E Mayo-Wilson","year":"2019","unstructured":"Mayo-Wilson E, Fusco N, Li T, et al. Harms are assessed inconsistently and reported inadequately Part 2: Non-systematic adverse events. J Clin Epidemiol. 2019;113:11\u20139. \n                    https:\/\/doi.org\/10.1016\/j.jclinepi.2019.04.020\n                    \n                  .","journal-title":"J Clin Epidemiol"},{"key":"3581_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jclinepi.2019.04.022","volume":"113","author":"E Mayo-Wilson","year":"2019","unstructured":"Mayo-Wilson E, Fusco N, Li T, et al. Harms are assessed inconsistently and reported inadequately Part 1: Systematic adverse events. J Clin Epidemiol. 2019;113:20\u20137. \n                    https:\/\/doi.org\/10.1016\/j.jclinepi.2019.04.022\n                    \n                  .","journal-title":"J Clin Epidemiol"},{"key":"3581_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jclinepi.2017.07.014","volume":"91","author":"E Mayo-Wilson","year":"2017","unstructured":"Mayo-Wilson E, Li T, Fusco N, et al. Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy. J Clin Epidemiol. 2017;91:95\u2013110. \n                    https:\/\/doi.org\/10.1016\/j.jclinepi.2017.07.014\n                    \n                  .","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"3581_CR25","doi-asserted-by":"publisher","first-page":"e1002127","DOI":"10.1371\/journal.pmed.1002127","volume":"13","author":"S Golder","year":"2016","unstructured":"Golder S, Loke YK, Wright K, et al. Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review. PLoS Med. 2016;13(9):e1002127. \n                    https:\/\/doi.org\/10.1371\/journal.pmed.1002127\n                    \n                  .","journal-title":"PLoS Med"},{"issue":"6","key":"3581_CR26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/ebmed-2016-110494","volume":"21","author":"NJA Halfpenny","year":"2016","unstructured":"Halfpenny NJA, Quigley JM, Thompson JC, et al. Value and usability of unpublished data sources for systematic reviews and network meta-analyses. Evid Based Med. 2016;21(6):208\u201313. \n                    https:\/\/doi.org\/10.1136\/ebmed-2016-110494\n                    \n                  .","journal-title":"Evid Based Med"},{"key":"3581_CR27","doi-asserted-by":"publisher","first-page":"d7202","DOI":"10.1136\/bmj.d7202","volume":"344","author":"B Hart","year":"2012","unstructured":"Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ. 2012;344:d7202. \n                    https:\/\/doi.org\/10.1136\/bmj.d7202\n                    \n                  .","journal-title":"BMJ"},{"issue":"7","key":"3581_CR28","doi-asserted-by":"publisher","first-page":"477","DOI":"10.7326\/M13-0480","volume":"160","author":"DM Hartung","year":"2014","unstructured":"Hartung DM, Zarin DA, Guise J-M, et al. Reporting discrepancies between the ClinicalTrials. gov results database and peer-reviewed publications. Ann Intern Med. 2014;160(7):477\u201383. \n                    https:\/\/doi.org\/10.7326\/M13-0480\n                    \n                  .","journal-title":"Ann Intern Med"},{"key":"3581_CR29","doi-asserted-by":"publisher","first-page":"CD008965","DOI":"10.1002\/14651858.CD008965.pub4","volume":"1","author":"T Jefferson","year":"2012","unstructured":"Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012;1:CD008965. \n                    https:\/\/doi.org\/10.1002\/14651858.CD008965.pub4\n                    \n                  .","journal-title":"Cochrane Database Syst Rev"},{"key":"3581_CR30","doi-asserted-by":"publisher","first-page":"h4320","DOI":"10.1136\/bmj.h4320","volume":"351","author":"J Le Noury","year":"2015","unstructured":"Le Noury J, Nardo JM, Healy D, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ. 2015;351:h4320. \n                    https:\/\/doi.org\/10.1136\/bmj.h4320\n                    \n                  .","journal-title":"BMJ"},{"issue":"12","key":"3581_CR31","doi-asserted-by":"publisher","first-page":"e1001566","DOI":"10.1371\/journal.pmed.1001566","volume":"10","author":"C Riveros","year":"2013","unstructured":"Riveros C, Dechartres A, Perrodeau E, et al. Timing and completeness of trial results posted at ClinicalTrials. gov and published in journals. PLoS Med. 2013;10(12):e1001566. \n                    https:\/\/doi.org\/10.1371\/journal.pmed.1001566\n                    \n                  .","journal-title":"PLoS Med"},{"key":"3581_CR32","doi-asserted-by":"publisher","first-page":"f3981","DOI":"10.1136\/bmj.f3981","volume":"346","author":"MA Rodgers","year":"2013","unstructured":"Rodgers MA, Brown JV, Heirs MK, et al. Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusion. BMJ. 2013;346:f3981. \n                    https:\/\/doi.org\/10.1136\/bmj.f3981\n                    \n                  .","journal-title":"BMJ"},{"key":"3581_CR33","volume-title":"ICH harmonised tripartite guideline: clinical safety data management: definitions and standards for expedited reporting E2A","author":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use","year":"1994","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: clinical safety data management: definitions and standards for expedited reporting E2A. 1994. \n                    http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E2A\/Step4\/E2A_Guideline.pdf\n                    \n                  ; Accessed 12 May 2018."},{"issue":"9","key":"3581_CR34","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1056\/NEJMsa1012065","volume":"364","author":"DA Zarin","year":"2011","unstructured":"Zarin DA, Tse T, Williams RJ, et al. The ClinicalTrials.gov results database--update and key issues. N Engl J Med. 2011;364(9):852\u201360. \n                    https:\/\/doi.org\/10.1056\/NEJMsa1012065\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"3581_CR35","volume-title":"ICH harmonised tripartite guideline: structure and content of clinical study reports E3","author":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use","year":"1995","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: structure and content of clinical study reports E3. 1995. \n                    http:\/\/www.ich.org\/products\/guidelines\/efficacy\/efficacy-single\/article\/structure-and-content-of-clinical-study-reports.html\n                    \n                  . Accessed 12 May 2018."},{"key":"3581_CR36","doi-asserted-by":"publisher","first-page":"i5078","DOI":"10.1136\/bmj.i5078","volume":"355","author":"N Lineberry","year":"2016","unstructured":"Lineberry N, Berlin JA, Mansi B, et al. Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry\/journal editor perspective. BMJ. 2016;355:i5078. \n                    https:\/\/doi.org\/10.1136\/bmj.i5078\n                    \n                  .","journal-title":"BMJ"},{"issue":"1","key":"3581_CR37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40266-019-00667-8","volume":"36","author":"G Honvo","year":"2019","unstructured":"Honvo G, Bannuru RR, Bruy\u00e8re O, et al. Recommendations for the reporting of harms in manuscripts on clinical trials assessing osteoarthritis drugs: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Drugs Aging. 2019;36(1):145\u201359.","journal-title":"Drugs Aging"},{"issue":"10","key":"3581_CR38","doi-asserted-by":"publisher","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","volume":"141","author":"JP Ioannidis","year":"2004","unstructured":"Ioannidis JP, Evans SJ, G\u00f8tzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781\u20138. \n                    https:\/\/doi.org\/10.7326\/0003-4819-141-10-200411160-00009\n                    \n                  .","journal-title":"Ann Intern Med"},{"key":"3581_CR39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13643-015-0134-z","volume":"4","author":"E Mayo-Wilson","year":"2015","unstructured":"Mayo-Wilson E, Hutfless S, Li T, et al. Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic review. Syst Rev. 2015;4:143. \n                    https:\/\/doi.org\/10.1186\/s13643-015-0134-z\n                    \n                   (Correction: 2018; 7:48).","journal-title":"Syst Rev"},{"key":"3581_CR40","doi-asserted-by":"publisher","first-page":"h4169","DOI":"10.1136\/bmj.h4169","volume":"351","author":"E Mayo-Wilson","year":"2015","unstructured":"Mayo-Wilson E, Doshi P, Dickersin K. Are manufacturers sharing data as promised? BMJ. 2015;351:h4169. \n                    https:\/\/doi.org\/10.1136\/bmj.h4169\n                    \n                  .","journal-title":"BMJ"},{"key":"3581_CR41","unstructured":"Stata Statistical Software: Release 14 [program]. College Station; 2015."},{"key":"3581_CR42","volume-title":"A multicenter, double-blind, randomized, placebo-controlled, double- dummy trial of the use of quetiapine fumarate (SEROQUEL [Registered]) in the treatment of patients with bipolar depression. Study code: 5077US\/0049","author":"AstraZeneca","year":"2005","unstructured":"AstraZeneca. A multicenter, double-blind, randomized, placebo-controlled, double- dummy trial of the use of quetiapine fumarate (SEROQUEL [Registered]) in the treatment of patients with bipolar depression. Study code: 5077US\/0049, 2005."},{"issue":"5","key":"3581_CR43","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1177\/1740774509344101","volume":"6","author":"BJ Crowe","year":"2009","unstructured":"Crowe BJ, Xia HA, Berlin JA, et al. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clin Trials. 2009;6(5):430\u201340.","journal-title":"Clin Trials"},{"issue":"6473","key":"3581_CR44","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1136\/bmj.290.6473.1002","volume":"290","author":"I Chalmers","year":"1985","unstructured":"Chalmers I. Proposal to outlaw the term \u201cnegative trial\u201d. BMJ. 1985;290(6473):1002.","journal-title":"BMJ"},{"issue":"3","key":"3581_CR45","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/1467-9876.00197","volume":"49","author":"J Hutton","year":"2000","unstructured":"Hutton J, Williamson PR. Bias in meta-analysis due to outcome variable selection within studies. J Roy Stat Soc C App. 2000;49(3):359\u201370. \n                    https:\/\/doi.org\/10.1111\/1467-9876.00197\n                    \n                  .","journal-title":"J Roy Stat Soc C App"},{"key":"3581_CR46","doi-asserted-by":"publisher","first-page":"c365","DOI":"10.1136\/bmj.c365","volume":"340","author":"JJ Kirkham","year":"2010","unstructured":"Kirkham JJ, Dwan KM, Altman DG, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ. 2010;340:c365. \n                    https:\/\/doi.org\/10.1136\/bmj.c365\n                    \n                  .","journal-title":"BMJ"},{"issue":"10","key":"3581_CR47","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/sim.2025","volume":"24","author":"PR Williamson","year":"2005","unstructured":"Williamson PR, Gamble C. Identification and impact of outcome selection bias in meta-analysis. Stat Med. 2005;24(10):1547\u201361. \n                    https:\/\/doi.org\/10.1002\/sim.2025\n                    \n                  .","journal-title":"Stat Med"},{"issue":"5","key":"3581_CR48","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1191\/0962280205sm415oa","volume":"14","author":"PR Williamson","year":"2005","unstructured":"Williamson PR, Gamble C, Altman DG, et al. Outcome selection bias in meta-analysis. Stat Methods Med Res. 2005;14(5):515\u201324. \n                    https:\/\/doi.org\/10.1191\/0962280205sm415oa\n                    \n                   [published Online First: 2005\/10\/27].","journal-title":"Stat Methods Med Res"},{"key":"3581_CR49","volume-title":"Food and Drug Administration Amendments Act, Section 801","author":"110th Congress of the United States of America","year":"2007","unstructured":"110th Congress of the United States of America. Food and Drug Administration Amendments Act, Section 801. 2007."},{"issue":"1","key":"3581_CR50","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jrsm.1277","volume":"9","author":"E Mayo-Wilson","year":"2018","unstructured":"Mayo-Wilson E, Li T, Fusco N, et al. Practical guidance for using multiple data sources in systematic reviews and meta-analyses (with examples from the MUDS study). Res Synth Methods. 2018;9(1):2\u201312. \n                    https:\/\/doi.org\/10.1002\/jrsm.1277\n                    \n                  .","journal-title":"Res Synth Methods"},{"key":"3581_CR51","doi-asserted-by":"publisher","unstructured":"Mayo-Wilson E, Golozar A, Cowley T, et al. Methods to identify and prioritize patient-centered outcomes for use in comparative effectiveness research. Pilot Feasibility Stud. 2018;4(95). \n                    https:\/\/doi.org\/10.1186\/s40814-018-0284-6\n                    \n                  .","DOI":"10.1186\/s40814-018-0284-6"},{"issue":"1","key":"3581_CR52","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1745-6215-15-247","volume":"15","author":"CA Prinsen","year":"2014","unstructured":"Prinsen CA, Vohra S, Rose MR, et al. Core Outcome Measures in Effectiveness Trials (COMET) initiative: protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a \u2018core outcome set\u2019. Trials. 2014;15(1):247.","journal-title":"Trials"},{"key":"3581_CR53","unstructured":"COMET Initiative. \n                    http:\/\/www.comet-initiative.org\/\n                    \n                  . Accessed 12 May 2018."},{"issue":"11","key":"3581_CR54","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1073\/pnas.1708273114","volume":"115","author":"K Dickersin","year":"2018","unstructured":"Dickersin K, Mayo-Wilson E. Standards for design and measurement would make clinical research reproducible and usable. P Natl Acad Sci USA. 2018;115(11):2590\u20134. \n                    https:\/\/doi.org\/10.1073\/pnas.1708273114\n                    \n                  .","journal-title":"P Natl Acad Sci USA"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3581-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T19:22:01Z","timestamp":1599160921000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3581-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3581"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3581-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.268\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.268\/v2","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"30 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study received an exemption from the Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB No: 00006324).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Up to 2008, KD served as an unpaid expert witness for Greene LLP, the plaintiffs\u2019 lawyers in litigation against Pfizer that provided several gabapentin documents used for this study. Swaroop Vedula was paid by the plaintiffs\u2019 attorneys for research assistance provided to KD for her work as an expert witness. Greene LLP provided a fund for scholarly research on reporting biases that provided salary support for NF and EMW.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"553"}}